Company profile
TScan Therapeutics, Inc.
NASDAQ:TCRXBiotechnology: Biological Products (No Diagnostic Substances)
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05973487 | phase1 | active_not_recruiting | 2024-05-06 | 2026-12-30 | TScan Therapeutics, Inc. | A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors |
| NCT05473910 | phase1 | recruiting | 2022-11-01 | 2026-06-01 | TScan Therapeutics, Inc. | A Phase 1/3 Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation |
| NCT07702578 | phase3 | recruiting | 2026-06-18 | 2029-06-01 | TScan Therapeutics, Inc. | A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation |
FDA applications (0)
No records yet.